Compounds > tenofovir
Page last updated: 2024-08-24

tenofovir and cmx 157

tenofovir has been researched along with cmx 157 in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (20.00)29.6817
2010's4 (80.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Aldern, KA; Almond, MR; Beadle, JR; De Clercq, E; Hostetler, KY; Korba, BE; Lampert, BM; Neyts, J; Painter, GR; Trost, LC1
Almond, MR; Buckheit, RW; Hartman, T; Keilholz, L; Lampert, BM; Lanier, ER; Mankowski, MK; Osterling, MC; Painter, GR; Ptak, RG1
Giesler, KE; Liotta, DC; Marengo, J1
Ensign, LM; Hoang, T; Hummert, P; Marzinke, MA; Parsons, TL1
Bensouda, S; Cone, RA; Date, AA; Ensign, LM; Fuchs, EJ; Gumber, S; Hanes, J; Hendrix, C; Hoang, T; Marzinke, M; Ortiz, JO; Rohan, L; Villinger, F; Xiao, P; Young, TW1

Other Studies

5 other study(ies) available for tenofovir and cmx 157

ArticleYear
Evaluation of hexadecyloxypropyl-9-R-[2-(Phosphonomethoxy)propyl]- adenine, CMX157, as a potential treatment for human immunodeficiency virus type 1 and hepatitis B virus infections.
    Antimicrobial agents and chemotherapy, 2007, Volume: 51, Issue:10

    Topics: Adenine; Animals; Anti-HIV Agents; Antiviral Agents; Cell Line; Female; Hepatitis B; Hepatitis B virus; HIV Core Protein p24; HIV Infections; HIV-1; Humans; Magnetic Resonance Spectroscopy; Male; Organophosphonates; Rats; Rats, Sprague-Dawley; Reverse Transcriptase Inhibitors; Tenofovir

2007
Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
    Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:7

    Topics: Adenine; Anti-HIV Agents; Cell Survival; Cells, Cultured; Drug Resistance, Viral; HIV Infections; HIV-1; Humans; Macrophages; Nucleosides; Nucleotides; Organophosphonates; Tenofovir

2010
Reduction Sensitive Lipid Conjugates of Tenofovir: Synthesis, Stability, and Antiviral Activity.
    Journal of medicinal chemistry, 2016, 08-11, Volume: 59, Issue:15

    Topics: Antiviral Agents; Dose-Response Relationship, Drug; Hep G2 Cells; Hepatitis B virus; HIV-1; Humans; Leukocytes, Mononuclear; Lipids; Microbial Sensitivity Tests; Models, Molecular; Molecular Structure; Structure-Activity Relationship; Tenofovir

2016
Validation and implementation of liquid chromatographic-mass spectrometric (LC-MS) methods for the quantification of tenofovir prodrugs.
    Journal of pharmaceutical and biomedical analysis, 2018, Apr-15, Volume: 152

    Topics: Adenine; Alanine; Anti-HIV Agents; Chromatography, Liquid; Humans; Organophosphonates; Prodrugs; Tandem Mass Spectrometry; Tenofovir

2018
Development of rectal enema as microbicide (DREAM): Preclinical progressive selection of a tenofovir prodrug enema.
    European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 2019, Volume: 138

    Topics: Adenine; Administration, Rectal; Alanine; Animals; Anti-HIV Agents; Anti-Infective Agents; Enema; HIV Infections; HIV-1; Homosexuality, Male; Male; Mice; Organophosphates; Organophosphonates; Pre-Exposure Prophylaxis; Prodrugs; Rectum; Sexual and Gender Minorities; Tenofovir

2019